You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2025

CLINICAL TRIALS PROFILE FOR ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT00245375 ↗ A Trial Comparing Combination Therapy of Acetaminophen Plus Ibuprofen Versus Tylenol #3 for the Treatment of Pain After Outpatient Surgery Completed McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. N/A 2005-01-01 Increasingly in general surgery, the investigators are conducting outpatient day surgery. Ambulatory surgery currently comprises 60 to 70% of surgeries performed in North America. These patients all require some form of analgesia which can be taken at home in the first few days after the surgery. The current standard at the investigators' centre and many others in the maritime provinces is to provide a prescription for oral acetaminophen plus codeine or oxycodone (Tylenol #3®, Percocet ®). Some patients may receive more potent opioids such as oral hydromorphone (Dilaudid®). Unfortunately, the most commonly prescribed medication (Tylenol #3®) is often poorly tolerated by patients, has several undesirable side effects, and may not provide effective pain relief. In the investigators' experience, non-steroidal anti-inflammatory drugs (NSAIDs) are uncommonly a routine addition to the home analgesic regimen. Tylenol #3®, in the investigators' experience and opinion, is a poor post surgical pain medication. They hope to show that a combination of ibuprofen and acetaminophen is better for pain relief after these procedures. The combination of acetaminophen and ibuprofen would be a safe, cheap, and readily available regimen. Unfortunately, as the prescribing practices of surgeons are old habits, it will require a very convincing argument to get them to change their practices. A randomized controlled trial comparing these two regimens, the investigators hope, would be a powerful enough argument. The hypothesis of this study, therefore, is that the pain control provided by a combination of acetaminophen plus ibuprofen (650 mg/400 mg four times per day) will be superior to Tylenol #3® (600 mg acetaminophen/60 mg codeine/15 mg caffeine four times per day). This study will attempt to enroll 150 patients in total. Eligible patients will be identified by their attending surgeon and contacted by study personnel. Patients who enroll in the study will undergo their surgery in the usual manner. After the surgery, in the recovery room, once they are ready to go home, they will be randomized to receive combination A or B and be given a week's worth of pain medication. They will then go home and take this medication as directed. They will record their pain intensity and pain relief once per day using a diary provided in the study package. One week after their surgery, they will return to the hospital clinic and be seen by the study nurse. They will hand over the diary and any unused medication. They will also be asked several questions regarding their overall satisfaction, incidence of side effects, and how long until they were pain free. The risks of participating in this study are minimal from the risks inherent to the procedures and medications the patients would receive within the standard of care. Ibuprofen is a commonly used NSAID which is widely available over the counter and has an established safety profile. The most common adverse effects of ibuprofen and other NSAIDs are gastrointestinal bleeding and ulceration. Other less common adverse effects include nephrotoxicity, hypersensitivity reactions, hepatic dysfunction (longterm use), and cognitive dysfunction. The investigators' patients will be selected to exclude those most at risk for these complications (see exclusion criteria). Acetaminophen has few side effects, with no adverse effects on platelet function and no evidence of gastric irritation.
OTC NCT00245375 ↗ A Trial Comparing Combination Therapy of Acetaminophen Plus Ibuprofen Versus Tylenol #3 for the Treatment of Pain After Outpatient Surgery Completed Nova Scotia Health Authority N/A 2005-01-01 Increasingly in general surgery, the investigators are conducting outpatient day surgery. Ambulatory surgery currently comprises 60 to 70% of surgeries performed in North America. These patients all require some form of analgesia which can be taken at home in the first few days after the surgery. The current standard at the investigators' centre and many others in the maritime provinces is to provide a prescription for oral acetaminophen plus codeine or oxycodone (Tylenol #3®, Percocet ®). Some patients may receive more potent opioids such as oral hydromorphone (Dilaudid®). Unfortunately, the most commonly prescribed medication (Tylenol #3®) is often poorly tolerated by patients, has several undesirable side effects, and may not provide effective pain relief. In the investigators' experience, non-steroidal anti-inflammatory drugs (NSAIDs) are uncommonly a routine addition to the home analgesic regimen. Tylenol #3®, in the investigators' experience and opinion, is a poor post surgical pain medication. They hope to show that a combination of ibuprofen and acetaminophen is better for pain relief after these procedures. The combination of acetaminophen and ibuprofen would be a safe, cheap, and readily available regimen. Unfortunately, as the prescribing practices of surgeons are old habits, it will require a very convincing argument to get them to change their practices. A randomized controlled trial comparing these two regimens, the investigators hope, would be a powerful enough argument. The hypothesis of this study, therefore, is that the pain control provided by a combination of acetaminophen plus ibuprofen (650 mg/400 mg four times per day) will be superior to Tylenol #3® (600 mg acetaminophen/60 mg codeine/15 mg caffeine four times per day). This study will attempt to enroll 150 patients in total. Eligible patients will be identified by their attending surgeon and contacted by study personnel. Patients who enroll in the study will undergo their surgery in the usual manner. After the surgery, in the recovery room, once they are ready to go home, they will be randomized to receive combination A or B and be given a week's worth of pain medication. They will then go home and take this medication as directed. They will record their pain intensity and pain relief once per day using a diary provided in the study package. One week after their surgery, they will return to the hospital clinic and be seen by the study nurse. They will hand over the diary and any unused medication. They will also be asked several questions regarding their overall satisfaction, incidence of side effects, and how long until they were pain free. The risks of participating in this study are minimal from the risks inherent to the procedures and medications the patients would receive within the standard of care. Ibuprofen is a commonly used NSAID which is widely available over the counter and has an established safety profile. The most common adverse effects of ibuprofen and other NSAIDs are gastrointestinal bleeding and ulceration. Other less common adverse effects include nephrotoxicity, hypersensitivity reactions, hepatic dysfunction (longterm use), and cognitive dysfunction. The investigators' patients will be selected to exclude those most at risk for these complications (see exclusion criteria). Acetaminophen has few side effects, with no adverse effects on platelet function and no evidence of gastric irritation.
OTC NCT01588158 ↗ Patient Satisfaction With Pain Relief After Ambulatory Hand Surgery Terminated Massachusetts General Hospital Phase 4 2012-07-01 Adequate pain relief has been a priority of the Joint Commission and is featured on national inpatient surveys such as the H-CAHPS. When considering methods for improving satisfaction with pain relief in the United States, a great deal of emphasis has been placed on opioid pain medications. Some of this emphasis on opioid pain medication is driven by the pharmaceutical industry and by advocacy groups with ties to the pharmaceutical industry. There is evidence that the "pain is the fifth vital sign" campaign of the Joint Commission led to an increased incidence of prescription of opioids, but there is less evidence of improved satisfaction with pain relief. There is some evidence of an increase in opioid-related adverse events. As the sales of opioids have tripled from 1999-2008, so has the number of deaths caused by opioid overdose; 14,800 in 2008. The number of visits to the Emergency Department for opioid overdose doubled between 2004 and 2008. Patients in other countries take far less opioid pain medication and are equally satisfied with pain relief. For instance, Lindenhovius et al. found in a retrospective study that Dutch patients take a weak (Tramadol) or no opioid pain medication after ankle fracture surgery and have comparable or better satisfaction with pain relief than American patients, most of whom take oxycodone. That study was repeated prospectively (unpublished) and confirmed that Dutch patients do not feel their pain is undertreated. A study of morphine use after a femur fracture demonstrated that American patients used far more than Vietnamese patients (30 mg/kg versus 0.9 mg/kg), but were more dissatisfied with their pain relief. These sociological differences are striking and suggest strongly that personal factors may be the most important determinant of satisfaction with pain relief. It is our impression that most American hand surgeons give patients a prescription for an opioid pain medication after carpal tunnel release, and that is certainly true in our practice. This seems to be based primarily on the outliers, and intended to avoid confrontation with patients that desire opioids; however, most patients take little or no narcotic pain medication, and many who do use the opioids complain of the side effects-nausea and pruritis in particular. It is therefore not clear whether routine opioids is the optimal pain management strategy after carpal tunnel release. In the study of Stahl et al. from Israel, patients were prescribed acetaminophen rather than opioids after carpal tunnel release and only 20 of 50 patients used acetaminophen; 30 patients did not use acetaminophen or other pain medication at all after the operation. Our aim is to determine if there is a difference in satisfaction with pain relief between patients advised to take opioids compared to patients advised to use over the counter acetaminophen after carpal tunnel release under local anesthesia. A secondary aim is to determine if personal factors account for more of the variability in satisfaction with pain relief than opioid strategy.
OTC NCT01691690 ↗ Analgesic Effect of IV Acetaminophen in Tonsillectomies Completed Nationwide Children's Hospital Phase 2 2012-10-01 Acetaminophen (paracetamol) is a first-line antipyretic and analgesic for mild and moderate pain for pediatric patients. Its common use (particularly in oral form) is underscored by its wide therapeutic window, safety profile, over the counter accessibility, lack of adverse systemic effects (as compared with NSAIDS and opioids) when given in appropriate doses. Although the exact anti-nociceptive mechanisms of acetaminophen continue to be elucidated, these mechanisms appear to be multi-factorial and include central inhibition of the cyclo-oxygenase (COX) enzyme leading to decreased production of prostaglandins from arachidonic acid, interference with serotonergic descending pain pathways, indirect activation of cannabinoid 1 (CB1) receptors and inhibition of nitric oxide pathways through N-methyl-D-aspartate (NMDA) or substance P. Of the above mechanisms, the most commonly known is that of central inhibition of COX enzymes by which the decreased production of prostaglandins diminish the release of excitatory transmitters of substance P and glutamate which are both involved in nociceptive transmission (Anderson, 2008; Smith, 2011). To date, several studies have shown acetaminophen's opioid sparing effect in the pediatric population when given by the rectal or intravenous routes (Korpela et al, 1999; Dashti et al, 2009; Hong et al, 2010).
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00092313 ↗ A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-182) Completed Merck Sharp & Dohme Corp. Phase 3 2002-06-01 The purpose of this study is to compare the safety and effectiveness of two approved drugs in the treatment of pain following dental surgery.
NCT00092326 ↗ A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-183) Completed Merck Sharp & Dohme Corp. Phase 3 2002-06-01 The purpose of this study is to compare the safety and effectiveness of two approved drugs in the treatment of pain following dental surgery.
NCT00245375 ↗ A Trial Comparing Combination Therapy of Acetaminophen Plus Ibuprofen Versus Tylenol #3 for the Treatment of Pain After Outpatient Surgery Completed McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. N/A 2005-01-01 Increasingly in general surgery, the investigators are conducting outpatient day surgery. Ambulatory surgery currently comprises 60 to 70% of surgeries performed in North America. These patients all require some form of analgesia which can be taken at home in the first few days after the surgery. The current standard at the investigators' centre and many others in the maritime provinces is to provide a prescription for oral acetaminophen plus codeine or oxycodone (Tylenol #3®, Percocet ®). Some patients may receive more potent opioids such as oral hydromorphone (Dilaudid®). Unfortunately, the most commonly prescribed medication (Tylenol #3®) is often poorly tolerated by patients, has several undesirable side effects, and may not provide effective pain relief. In the investigators' experience, non-steroidal anti-inflammatory drugs (NSAIDs) are uncommonly a routine addition to the home analgesic regimen. Tylenol #3®, in the investigators' experience and opinion, is a poor post surgical pain medication. They hope to show that a combination of ibuprofen and acetaminophen is better for pain relief after these procedures. The combination of acetaminophen and ibuprofen would be a safe, cheap, and readily available regimen. Unfortunately, as the prescribing practices of surgeons are old habits, it will require a very convincing argument to get them to change their practices. A randomized controlled trial comparing these two regimens, the investigators hope, would be a powerful enough argument. The hypothesis of this study, therefore, is that the pain control provided by a combination of acetaminophen plus ibuprofen (650 mg/400 mg four times per day) will be superior to Tylenol #3® (600 mg acetaminophen/60 mg codeine/15 mg caffeine four times per day). This study will attempt to enroll 150 patients in total. Eligible patients will be identified by their attending surgeon and contacted by study personnel. Patients who enroll in the study will undergo their surgery in the usual manner. After the surgery, in the recovery room, once they are ready to go home, they will be randomized to receive combination A or B and be given a week's worth of pain medication. They will then go home and take this medication as directed. They will record their pain intensity and pain relief once per day using a diary provided in the study package. One week after their surgery, they will return to the hospital clinic and be seen by the study nurse. They will hand over the diary and any unused medication. They will also be asked several questions regarding their overall satisfaction, incidence of side effects, and how long until they were pain free. The risks of participating in this study are minimal from the risks inherent to the procedures and medications the patients would receive within the standard of care. Ibuprofen is a commonly used NSAID which is widely available over the counter and has an established safety profile. The most common adverse effects of ibuprofen and other NSAIDs are gastrointestinal bleeding and ulceration. Other less common adverse effects include nephrotoxicity, hypersensitivity reactions, hepatic dysfunction (longterm use), and cognitive dysfunction. The investigators' patients will be selected to exclude those most at risk for these complications (see exclusion criteria). Acetaminophen has few side effects, with no adverse effects on platelet function and no evidence of gastric irritation.
NCT00245375 ↗ A Trial Comparing Combination Therapy of Acetaminophen Plus Ibuprofen Versus Tylenol #3 for the Treatment of Pain After Outpatient Surgery Completed Nova Scotia Health Authority N/A 2005-01-01 Increasingly in general surgery, the investigators are conducting outpatient day surgery. Ambulatory surgery currently comprises 60 to 70% of surgeries performed in North America. These patients all require some form of analgesia which can be taken at home in the first few days after the surgery. The current standard at the investigators' centre and many others in the maritime provinces is to provide a prescription for oral acetaminophen plus codeine or oxycodone (Tylenol #3®, Percocet ®). Some patients may receive more potent opioids such as oral hydromorphone (Dilaudid®). Unfortunately, the most commonly prescribed medication (Tylenol #3®) is often poorly tolerated by patients, has several undesirable side effects, and may not provide effective pain relief. In the investigators' experience, non-steroidal anti-inflammatory drugs (NSAIDs) are uncommonly a routine addition to the home analgesic regimen. Tylenol #3®, in the investigators' experience and opinion, is a poor post surgical pain medication. They hope to show that a combination of ibuprofen and acetaminophen is better for pain relief after these procedures. The combination of acetaminophen and ibuprofen would be a safe, cheap, and readily available regimen. Unfortunately, as the prescribing practices of surgeons are old habits, it will require a very convincing argument to get them to change their practices. A randomized controlled trial comparing these two regimens, the investigators hope, would be a powerful enough argument. The hypothesis of this study, therefore, is that the pain control provided by a combination of acetaminophen plus ibuprofen (650 mg/400 mg four times per day) will be superior to Tylenol #3® (600 mg acetaminophen/60 mg codeine/15 mg caffeine four times per day). This study will attempt to enroll 150 patients in total. Eligible patients will be identified by their attending surgeon and contacted by study personnel. Patients who enroll in the study will undergo their surgery in the usual manner. After the surgery, in the recovery room, once they are ready to go home, they will be randomized to receive combination A or B and be given a week's worth of pain medication. They will then go home and take this medication as directed. They will record their pain intensity and pain relief once per day using a diary provided in the study package. One week after their surgery, they will return to the hospital clinic and be seen by the study nurse. They will hand over the diary and any unused medication. They will also be asked several questions regarding their overall satisfaction, incidence of side effects, and how long until they were pain free. The risks of participating in this study are minimal from the risks inherent to the procedures and medications the patients would receive within the standard of care. Ibuprofen is a commonly used NSAID which is widely available over the counter and has an established safety profile. The most common adverse effects of ibuprofen and other NSAIDs are gastrointestinal bleeding and ulceration. Other less common adverse effects include nephrotoxicity, hypersensitivity reactions, hepatic dysfunction (longterm use), and cognitive dysfunction. The investigators' patients will be selected to exclude those most at risk for these complications (see exclusion criteria). Acetaminophen has few side effects, with no adverse effects on platelet function and no evidence of gastric irritation.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

Condition Name

Condition Name for ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE
Intervention Trials
Pain, Postoperative 25
Pain 17
Postoperative Pain 14
Opioid Use 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE
Intervention Trials
Pain, Postoperative 62
Acute Pain 13
Fractures, Bone 9
Osteoarthritis 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

Trials by Country

Trials by Country for ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE
Location Trials
United States 279
Canada 16
China 2
Puerto Rico 2
Belgium 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE
Location Trials
New York 31
California 27
Pennsylvania 18
Texas 14
North Carolina 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE
Clinical Trial Phase Trials
PHASE4 3
PHASE3 4
PHASE2 3
[disabled in preview] 65
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE
Clinical Trial Phase Trials
COMPLETED 60
Recruiting 28
Terminated 19
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

Sponsor Name

Sponsor Name for ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE
Sponsor Trials
Montefiore Medical Center 8
Purdue Pharma LP 7
University of California, Los Angeles 7
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE
Sponsor Trials
Other 165
Industry 38
U.S. Fed 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials Update, Market Analysis, and Projection for Acetaminophen and Oxycodone Hydrochloride

Last updated: October 28, 2025

Introduction

The combination of acetaminophen and oxycodone hydrochloride remains a cornerstone in pain management, particularly for moderate to severe pain. As the global opioid landscape evolves amidst regulatory scrutiny and burgeoning alternatives, understanding recent clinical trial developments, market dynamics, and future projections is essential for industry stakeholders. This analysis consolidates current insights into clinical trials, analyzes market performance, and projects future trends for these pharmaceuticals.

Clinical Trials Landscape: Acetaminophen & Oxycodone Hydrochloride

Current State of Clinical Research

Recent years have witnessed a shift toward optimizing combination therapies incorporating oxycodone hydrochloride with acetaminophen, driven by the need for efficacious yet safer analgesic options. Data from ClinicalTrials.gov indicate a modest but steady pipeline of trials evaluating new formulations, abuse deterrent technologies, and alternative dosing strategies. Notably:

  • Abuse-Deterrent Formulations (ADFs): Multiple ongoing studies aim to mitigate the abuse potential associated with oxycodone-based products. Examples include reformulations incorporating physical or chemical barriers [1].

  • Extended-Release (ER) Formulations: Continuous research assesses long-term safety, efficacy, and abuse-deterrence of ER formulations to address chronic pain management needs.

  • Pharmacogenomic Studies: Emerging trials explore genetic factors affecting patient response and risk of adverse events, aiming to individualize therapy.

Regulatory and Safety Considerations

The U.S. Food and Drug Administration (FDA) has issued guidance emphasizing the importance of safety monitoring, especially regarding hepatotoxicity risks from acetaminophen and dependence issues linked to oxycodone. Recent trials emphasize evaluating maximum safe dosages and alternative combinations to reduce adverse effects, aligning with regulatory trends.

Implications of Clinical Data

While no groundbreaking new drugs combining acetaminophen and oxycodone have emerged lately, incremental improvements—particularly through abuse-deterrent and sustained-release formulations—are evident. These developments reflect industry efforts to balance efficacy with safety, aligning with evolving regulatory expectations.

Market Analysis

Market Size and Trends

The global opioid analgesics market, which encompasses oxycodone hydrochloride, was valued at approximately USD 8.6 billion in 2022, with predictions to reach USD 12 billion by 2028, exhibiting a CAGR of around 5.8% [2].

Acetaminophen, while a non-opioid analgesic, complements oxycodone formulations, especially fixed-dose combinations. The combined market for opioid-acetaminophen products accounts for a significant share in pain therapeutics, primarily driven by North America and Europe.

Key Market Drivers

  • Rising Chronic Pain Prevalence: Increased incidences of osteoarthritis, low back pain, and cancer-related pain sustain demand.
  • Regulatory Landscape: Stricter regulations catalyze innovation in abuse-deterrent formulations, prolonging market relevance.
  • Off-Label and Multimodal Use: Growing acceptance of multimodal analgesia enhances sales of combination products.
  • Generic Competition: Patent expirations, notably of blockbuster formulations, foster market entry of generics, decreasing prices and expanding accessibility.

Market Challenges

  • Regulatory and Legal Risks: Increased oversight, crackdowns on opioid prescribing, and litigation threaten market stability.
  • Public Epidemic of Opioid Dependence: Heightened awareness and educational campaigns reduce prescribing rates, particularly in North America.
  • Availability of Alternatives: Non-opioid analgesics, such as NSAIDs, anticonvulsants, and neuromodulators, pose substitution threats.
  • Supply Chain and Manufacturing Disruptions: Factors like drug shortages and manufacturing constraints influence availability and pricing.

Competitive Landscape

Major players include Purdue Pharma (now bankrupt, with legacy products), Endo Pharmaceuticals, Teva, and Mallinckrodt. Several new entrants focus on abuse-deterrent technologies or novel delivery systems. The generic segment dominates, contributing estimated 70% of the market share.

Market Projections

Short-Term Outlook (Next 3 Years)

  • Continued growth driven by aging populations and increasing management of chronic pain.
  • Rising demand for abuse-deterrent formulations to meet regulatory mandates.
  • Generic penetration will intensify, leading to price reductions.
  • Short-term impact of regulatory crackdowns may temporarily slow sales growth, especially in North America.

Long-Term Outlook (Next 5-10 Years)

  • Transition towards alternative therapies (e.g., cannabinoids, neuromodulators) may temper growth, but the need for effective analgesics sustains demand.
  • Innovation in delivery systems (e.g., implantable pumps, transdermal patches) could open new markets.
  • Increasing adoption of digital health tools to monitor opioid use may influence prescribing patterns.
  • Regulatory pressures will intensify, likely favoring products with enhanced safety profiles and abuse-resistant features.

Future Trends and Opportunities

  • Innovation in Formulation: Enhanced abuse-deterrent and sustained-release features will be essential to maintain market share.
  • Personalized Medicine: Pharmacogenomic insights offer tailored therapy, potentially improving safety profiles.
  • Alternative Pain Management: Growing focus on non-opioid options could reshape the market landscape, emphasizing the importance of integrating new modalities.
  • Policy and Regulation: Stringent prescribing guidelines necessitate strategic alignment, with manufacturers investing in compliance and safety innovations.

Key Takeaways

  • Clinical trials primarily focus on enhancing safety and minimizing abuse potential, indicating ongoing industry commitment to addressing opioid crises.
  • The market for oxycodone hydrochloride and acetaminophen formulations remains significant but faces headwinds from regulatory, legal, and societal challenges.
  • Innovation—particularly in abuse-deterrent formulations and alternative delivery systems—presents opportunities for differentiation and growth.
  • Strategic collaboration with regulatory bodies and emphasis on safety will be crucial in sustaining market relevance amid ongoing reforms.
  • Diversification into non-opioid pain therapeutics is an essential consideration for long-term resilience.

FAQs

  1. What are the recent clinical trial advancements for oxycodone-acetaminophen formulations?
    Recent trials focus on abuse-deterrent formulations, extended-release options, and pharmacogenomic profiling to optimize safety and efficacy, reflecting industry efforts to address opioid misuse concerns.

  2. How is the market for oxycodone-acetaminophen products expected to evolve?
    The market will experience steady growth driven by chronic pain prevalence, but growth may slow due to regulatory restrictions and the rise of alternative therapies. Innovation in safety features remains critical.

  3. Are there new formulations in development aiming to reduce abuse?
    Yes, multiple formulations incorporate physical and chemical barriers designed to deter crushing and inhalation, with some products currently undergoing clinical evaluation or awaiting regulatory approval.

  4. What are the main challenges facing manufacturers of these analgesics?
    Challenges include regulatory hurdles, societal pushback against opioids, legal liabilities, competition from non-opioid therapies, and patent expirations impacting profitability.

  5. What opportunities exist for differentiating oxycodone-acetaminophen products?
    Opportunities include developing advanced abuse-deterrent technologies, integrating smart delivery systems, and expanding into multimodal analgesic approaches with improved safety profiles.


References

[1] ClinicalTrials.gov. (2023). Trials involving abuse-deterrent formulations of oxycodone.
[2] MarketWatch. (2023). Global opioids analgesics market forecast.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.